A newly published case report of paraneoplastic neurologic syndrome in a 65-year-old woman offers three essential takeaways for clinicians managing patients with unexplained neurological deterioration.
First, recognize that neurological symptoms frequently precede cancer diagnosis by significant intervals—sometimes months or years. Second, understand that small cell lung cancer causes approximately 50% of paraneoplastic syndromes, making it the leading malignancy to screen for in these patients. Third, implement early antibody testing as a diagnostic tool: detecting paraneoplastic antibodies can guide targeted cancer screening before imaging studies reveal malignancy, potentially accelerating diagnosis and treatment initiation.
For patients presenting with progressive, unexplained neurological symptoms—particularly those with atypical presentations that don’t fit conventional neurological diagnoses—paraneoplastic syndrome should remain on the differential. Early recognition through appropriate antibody testing transforms diagnostic outcomes and enables clinicians to identify life-threatening underlying malignancies when they are most treatable.
Read the full article on GMJ Newsroom.
Was this article helpful?
